血塞通脉冲控释片的处方优化  

Optimization of the Formulation of Xuesaitong Pulsed Sustained-release Tablets

作　　者：周金彩[1] 龙红萍[2] 杨栋梁[1,3] 何蓉[1] 任娜[1,3] 

机构地区：[1]湖南科技职业学院,长沙410004 [2]中南大学药学院,长沙410013 [3]中南大学化学化工学院,长沙410083

出　　处：《中国药房》2014年第7期611-613,共3页China Pharmacy

基　　金：湖南省科学技术厅科技计划一般项目(No.2011FJ6007)

摘　　要：目的:优化血塞通脉冲控释片的处方。方法:采用单因素试验考察片芯崩解剂种类、片芯崩解剂用量、包衣液组成和包衣增重百分率对药物累积释放率的影响;采用正交试验考察片芯崩解剂用量、包衣液组成、包衣增重百分率对释药时滞时间的影响,优化血塞通脉冲控释片的处方。结果:最佳处方为片芯崩解剂用量为15%,包衣增重百分率为9%,包衣液组成为Eudragit L100∶EC=1.5∶1(m/m);在该处方条件下,血塞通脉冲片的体外释药时滞为6 h左右,然后迅速脉冲式释药。结论:所选处方合理,制备的血塞通脉冲控释片能达到设计要求,体外试验可达到脉冲释药时滞效果。OBJECTIVE： To optimize the formulation of Xuesaitong pulsed sustained-release tablets. METHODS： Effects of the type and amount of tablet core disintegrating agent, the constitution and weight percentage of coating solution on drug release rate were investigated by single factor test. The formulation of Xuesaitong pulsed sustained-release tablets was optimized by orthogohai design through investigating effects of amount of tablet core disintegrating agent, the constitution and weight percentage of coating solution on drug release time-lag. RESULTS： The optimal formulation was as follows： tablet core disintegrating agent of 15%, the percentage of coating weight 9 %, coating solution consisting of Eudragit L100 ：EC=1.5：1（m/m）. Under the condition, drug release time-lag of the tablet was about 6 h in vitro, and then the tablet was released in pulsed model. CONCLUSIONS： The formulation is reasonable, and prepared Xuesaitong pulsed sustained-release tablets achieve the goal of design. Drug release of the tablet in vitro meets the demand of drug release time-lag.

关 键 词：血塞通 脉冲控释片 时滞 体外释放度 

分 类 号：R284.2[医药卫生—中药学] R283[医药卫生—中医学]